Approval Of Servier’s Voranigo For Certain Brain Tumors Validates Oncology Strategy
Executive Summary
The drug prolonged progression-free survival by 16.6 months in Phase III. Chief commercial officer Arjun Prasad talked about the company’s launch plans in an interview.